Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05599217
Other study ID # HX-B-2022062
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 13, 2023
Est. completion date March 31, 2025

Study information

Verified date April 2024
Source Beijing Tiantan Hospital
Contact Liang Wu, M.D.
Phone 15001333582
Email jasewl@sina.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

A prospective, multicenter, case control trial is designed to compare difference in dietary and nutritional factors in patients with and without chronic subdural hematoma.


Description:

Chronic subdural hematoma (CSDH) is one of the most common neurosurgical conditions, which is considered to be an inflammatory disease. Dietary factors can have an impact on the inflammatory mechanism in human body, which can increase a variety of inflammatory biomarkers in the blood. The risk of malnutrition in the elderly is generally high, and nutritional status can affect the risk of CSDH in the elderly. Little is known about the association of dietary factors with CSDH. The investigators speculate that dietary factors participate in and promote the occurrence and development of CSDH. This study will clarify whether there is a correlation between dietary factors and CSDH, which will reveal the pathogenesis and prevention of CSDH.


Recruitment information / eligibility

Status Recruiting
Enrollment 420
Est. completion date March 31, 2025
Est. primary completion date December 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 90 Years
Eligibility Case group (CSDH group) Inclusion Criteria: - Patients (18 years to 90 years) presenting with clinical symptoms and neurological deficits of CSDH. - CSDH verified on cranial computed tomography or magnetic resonance imaging. - Written informed consent from patients or their next of kin according to the patient's cognitive status. Control group (Healthy group) Inclusion Criteria: - non-CSDH patients (18 years to 90 years) with matched age and gender. - Written informed consent from patients or their next of kin according to the patient's cognitive status. Exclusion Criteria for both case and control group: - Previous intracranial surgery for any neurological disorders but chronic subdural hematoma before. - CSDH turned from acute subdural hematoma. - Existing malignant tumors, poor medication condition or severe comorbidity. - Difficulty in feeding requiring long-term enteral or parenteral nutrition support. - Dietary and nutritional survey is estimated to be completed difficultly. - Reproductive-age women without verified negative pregnancy testing. - Participating in other research.

Study Design


Intervention

Other:
Dietary and nutritional questionnaire
Nutrition assessment, nutrient intake, dietary inflammatory index, and frailty status will be examined using questionnaires.
Neurological function, cognitive function, and life quality assessment
Neurological function, cognitive function, and life quality will be examined using Glasgow Coma Scale, Modified Rankin Scale, Markwalder Grade Scale, Mini-mental state examination, and EuroQol five dimensions questionnaire.
Peripheral blood test
Collect peripheral blood samples from patients.
Metabonomic test
Collect urine and stool samples from patients.
Hematoma test
Collect hematoma fluid, dura mater, and hematoma outer membrane samples from patients.

Locations

Country Name City State
China Beijing Tiantan Hospital, Capital Medical University Beijing
China Huangshan City People's Hospital Huangshan Anhui
China First People's Hospital of Lianyungang Lianyungang Jiangsu
China People's Hospital of Ningxia Hui Autonomous Region Yinchuan Ningxia

Sponsors (1)

Lead Sponsor Collaborator
Beijing Tiantan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Difference in dietary intakes Difference in dietary intakes assessed by Food Frequency Questionnaire, a common method for measuring dietary intake in large epidemiological studies. When subjects are enrolled
Primary Difference in Dietary Inflammatory Index score The Dietary Inflammatory Index (DII) score of the current nutritional status of patients with and without CSDH will be evaluated. The amounts of nutrients will be calculated using last 3-month nutrient analysis program. DII score will calculate from these foods. The z-score must first be calculated. To calculate the z-score, the standard global consumption amount is subtracted from the average consumption amount of the individual. The result obtained is divided by the standard deviation value. The z score found with this result is converted to the percentile score. The percentile value is multiplied by the full inflammatory effect score. DII is obtained as a result of summing the scores calculated for all nutrients. Found DII is an indicator of the inflammatory load of the individual's daily diet. When subjects are enrolled
Primary Difference in nutritional status Difference in nutritional status measured by Mini-Nutritional Assessment. When subjects are enrolled
Primary Difference in frailty status Difference in frailty status measured by Modified Frailty Index. Modified Frailty Index ranges from score 0 to 1, and frail status is defined as a score of =0.27. When subjects are enrolled
Secondary Difference in gut microbiota measured by 16S rRNA between case group and control group Fecal sample will be measured by 16S rRNA sequencing. The alpha and beta diversity of gut microbiota between the groups will be analyzed, including a series of statistical analysis indexes such as Chao, Shannon, Simpsonace, Simpson and Coverage, in order to reflect the microbial community diversity. Based on the results of species annotation, the community histogram, the community heatmap and the Wayne map will be used to analyze the species composition of the sample, in order to explore the relationship between the species and the sample, and analyze the key microflora in the sample. The PCA, PCoA and NMDS analysis will be used to assess the similarities and differences in species composition between groups. To further screen the species with significant differences, the LEfSe difference discriminant analysis will be used. When subjects are enrolled
Secondary Difference in metabolomics of gut, urine, and serum between case group and control group Changes of metabolites in gut, urine, and serum will be measured by metabolomic mass spectrometry. When subjects are enrolled
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06347796 - Chronic Subdural Hematoma Treatment With Embolization Versus Surgery Study N/A
Recruiting NCT04065113 - Middle Meningeal Artery Embolization for Chronic Subdural Hematoma N/A
Recruiting NCT02938468 - Mgt of Chronic Subdural Hematoma Using Dexamethasone Phase 2/Phase 3
Completed NCT03307395 - Middle Meningeal Artery Embolization for Treatment of Chronic Subdural Hematoma N/A
Terminated NCT04502745 - A Study to Evaluate Endoscope-assisted, Minimally-invasive Cortical Access System for Chronic Subdural Evacuation N/A
Terminated NCT03353259 - Tocilizumab (RoActemra) and Tranexamic Acid (Cyklokapron) Used as Adjuncts to Chronic Subdural Hematoma Surgery Phase 2/Phase 3
Recruiting NCT02568124 - Tranexamic Acid in Chronic Subdural Hematomas Phase 2/Phase 3
Completed NCT02282228 - Detecting Chronic Subdural Hematoma With Microwave Technology N/A
Recruiting NCT05143216 - High Concentration Oxygen Therapy for Pneumocephalus in Chronic Subdural Haematoma: A Prospective Observational Study
Active, not recruiting NCT04816591 - Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA N/A
Recruiting NCT06401772 - The Effectiveness and Safety of Body Posture in Preventing Postoperative Recurrence for Chronic Subdural Hematoma N/A
Completed NCT06134206 - Burr Hole Ultrasound Study N/A
Recruiting NCT03666949 - General Anesthesia Versus Locoregional Anesthesia for Evacuation of Chronic Subdural Hematoma N/A
Recruiting NCT03280212 - Tranexamic Acid in the Treatment of Residual Chronic Subdural Hematoma Phase 3
Completed NCT03447327 - Outcome of Single Burr Hole Under Local Anaesthesia in the Management of Chronic Subdural Hematoma N/A
Recruiting NCT05374681 - Efficacy of a Minimally Invasive Therapy Adjuvant to the Standards of Care by Cyanoacrylate Embolization N/A
Recruiting NCT05267184 - Swedish Trial on Embolization of Middle Meningeal Artery Versus Surgical Evacuation in Chronic Subdural Hematoma N/A
Not yet recruiting NCT05900557 - Neurologic Deficits and Recovery in Chronic Subdural Hematoma N/A
Completed NCT02757235 - The Swedish Study of Irrigation Fluid Temperature in the Evacuation of Chronic Subdural Hematoma N/A
Terminated NCT02111785 - Dexamethasone Versus Burr Hole Craniostomy for Symptomatic Chronic Subdural Hematoma Phase 2/Phase 3